We preserved the innovative business and retained its right to produce a unique product in the Russian market
About the client
Nanobiotech is an innovative enterprise based on the Chemical Faculty of Lomonosov Moscow State University. The company specializes in the commercialization of scientific advancements in the fields of chemistry and nanotechnology. The employees developed and successfully launched a range of innovative medications based on silver nanoparticles.
Protect the company’s rights and prove in court that the contractor, AgroKhimProm, cannot independently continue producing and selling medications that are based on Nanobiotech’s proprietary technologies.
The experts at Nanobiotech developed the medications and conducted designer supervision. Pursuant to the service agreement, AgroKhimProm manufactured and distributed agricultural medications based on silver nanoparticles.
AgroKhimProm refused to enter into a licensing agreement. They continued manufacturing and selling the medications, unlawfully utilizing the developments of Nanobiotech.
How we resolved it
  • We won a series of court cases, representing the interests of Nanobiotech in disputes against member companies of AgroKhimProm Group, including Agrokhimiya-Novosergiyevka, Agro Reserve Altai, Alvita, and RusAgroSbyt
  • Through strategic organization, we managed to preserve the right to the technology and production for the authoring company, even in the absence of primary documentation
Despite the corporate conflict, the client successfully maintained their business. In several cases, we were able to prove the provision of services and successfully defend against the claims seeking over RUB 20 mln, even in the absence of a significant portion of primary documentation.

We also managed to convince the court that a participant with a 50% stake in the company does not need to provide company documentation, as doing so could harm the interests of the company.

We successfully recovered approximately RUB 20 mln from the company that attempted to unlawfully utilize our client’s developments.
More cases